aTyr Pharma Inc
471A
Company Profile
Business description
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Contact
10240 Sorrento Valley Road
Suite 300
San DiegoCA92121
USAT: +1 858 731-8389
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
58
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,897.00 | 59.20 | -0.66% |
| CAC 40 | 8,081.43 | 41.98 | -0.52% |
| DAX 40 | 25,266.53 | 144.10 | -0.57% |
| Dow JONES (US) | 51,349.98 | 161.61 | -0.31% |
| FTSE 100 | 10,679.99 | 25.27 | -0.24% |
| HKSE | 24,761.13 | 72.99 | -0.29% |
| NASDAQ | 26,939.37 | 3.34 | 0.01% |
| Nikkei 225 | 65,513.99 | 495.04 | 0.76% |
| NZX 50 Index | 13,797.12 | 27.71 | -0.20% |
| S&P 500 | 7,704.13 | 1.90 | -0.02% |
| S&P/ASX 200 | 8,702.00 | 63.30 | -0.72% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |